THU0261 Outcomes in Systemic Lupus Erythematous (SLE) Patients with High Disease Activity Treated with Belimumab: Results from an Observational Study in the United States (U.S.)

Background Post hoc analyses of belimumab BLISS trials identified baseline factors generally associated with high disease activity as predictors of improved response to treatment, such as SELENA-SLEDAI (SS)> 10, low complement levels, anti-dsDNA positivity and glucocorticoid therapy. Objectives W...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of the rheumatic diseases 2013-06, Vol.72 (Suppl 3), p.A253-A254
Hauptverfasser:	Kan, H., Collins, C., Dall’Era, M., McGuire, M. B., Koscielny, V., Pappu, R., Molta, C.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!